0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Nonspecific Guidelines Lead to Inappropriate Fluoroquinolone Use

Join Y. Luh, MD; Bernard M. Karnath, MD
Arch Intern Med. 2003;163(13):1617-1618. doi:10.1001/archinte.163.13.1617-a.
Text Size: A A A
Published online

Extract

Although a small study, the article by Lautenbach et al1 underscores the alarming prevalence of inappropriate fluoroquinolone use in a sample of emergency departments. Particularly in the setting of community-acquired pneumonia (CAP), the widespread use of fluoroquinolones has led to emergence of not only resistant pneumococci, but also a host of gram-negative organisms that often have nothing to do with the cause of a patient's pneumonia.2 One of the problems of influencing practitioners treating CAP to limit the use of fluoroquinolones to those deemed appropriate for such therapy1 is the lack specific recommendations for the treatment of CAP by guidelines published by the American Thoracic Society and Infectious Diseases Society of America (IDSA). In outpatient CAP, the IDSA recommends doxycycline, a macrolide, or a fluoroquinolone in no specific order of preference.3 In stable, hospitalized patients, the American Thoracic Society recommends an intravenous β-lactam plus an intravenous or oral macrolide, or doxycycline, or an intravenous fluoroquinolone alone, as equivalent recommendations for first-line therapy.4 In this same population of patients, the IDSA recommends an extended-spectrum cephalosporin plus a macrolide, or a β-lactam/lactamase inhibitor plus a macrolide, or a fluoroquinolone alone—equally as first-line therapy. Only the Centers for Disease Control Drug Resistant Streptococcus pneumoniae Therapeutic Working Group and the Antibiotic Selection for Community Acquired Pneumonia panel consistently recognize the potential impact of widespread fluoroquinolone resistance due to its widespread use, as well as the need to reserve fluoroquinolones for selected patients with CAP, in the outpatient, inpatient, and intensive care unit settings.5,6 Nevertheless, even with well-established widely disseminated local hospital guidelines that specifically addressed the issue of appropriate fluoroquinolone use, the vast majority of fluoroquinolone use was still inappropriate.1 In view of such variance in national guidelines, as well as poor compliance with local hospital guidelines, it is not surprising that confusion over what should be considered first-line empiric therapy for CAP has led to a high level of inappropriate use of fluoroquinolones in the outpatient and inpatient settings. Any hope of limiting emergence of fluoroquinolone resistance will require major interventions in educating health care providers on the appropriate use of fluoroquinolones in our hospitals, emergency departments, and clinics, not only for CAP, but for many other infectious diseases as well.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();